Today: 9 June 2026
BellRing Brands (BRBR) steadies in premarket after 9% slide as law-firm probe adds overhang
30 December 2025
1 min read

BellRing Brands (BRBR) steadies in premarket after 9% slide as law-firm probe adds overhang

NEW YORK, December 30, 2025, 08:01 ET — Premarket

  • BellRing Brands shares were little changed before the open after a steep drop in the prior session.
  • A shareholder law firm said it opened a securities-fraud investigation into the Premier Protein maker.
  • Investors are looking ahead to the company’s next results, estimated for early February.

BellRing Brands Inc shares were down 0.1% in premarket trading on Tuesday at about $27.3, after sliding roughly 9% in the previous session.

The move matters because BellRing’s next quarter will be the first full read-through on its fiscal 2026 outlook after a volatile stretch for the stock. Investors are focused on whether demand for convenient nutrition is holding up as retailers manage inventories and promotions.

It also lands at a sensitive moment for the company’s story: how much of its sales momentum comes from consumers buying through at the shelf versus shipments to retailers. That distinction can change how traders model growth and margins.

Bleichmar Fonti & Auld LLP said on Monday it is investigating BellRing for potential violations of federal securities laws. The firm alleged BellRing’s growth may have been boosted by “trade inventory loading” — shipping extra product to retailers to build inventory — rather than sustainable end-consumer demand, according to the release.

On Monday, BRBR opened at $30.15, fell to as low as $26.67 and ended the session at $27.33 on volume of about 4.48 million shares, Investing.com data showed. Traders will be watching whether the stock holds the late-December low near $26.7, with the prior close around $30.2 now acting as a near-term hurdle.

A Form 4 filing on Monday showed director Elliot H. Stein Jr reporting a transaction involving 4,916 shares at a price of $0, described as a transfer and a correction to prior beneficial ownership reporting.

The broader market was slightly softer in early trading, with the S&P 500-tracking SPDR ETF down about 0.4% and the Nasdaq 100-tracking QQQ down about 0.5%.

BellRing last reported quarterly results on Nov. 18, when it missed analysts’ earnings-per-share expectations and issued fiscal 2026 revenue guidance of about $2.4 billion to $2.5 billion, MarketBeat data showed. MarketBeat also lists the next earnings date as estimated for Feb. 2, after the market close.

In the meantime, investors will watch for any further legal developments tied to the investigation and for any new disclosures in regulatory filings. The next earnings call will also be the next clear chance for management to address retailer inventory trends, promotional intensity and cost pressures in more detail.

Stock Market Today

  • ASX Value Stocks Trading Below Estimated Worth in June 2026
    June 9, 2026, 3:45 PM EDT. Australian securities are showing value opportunities as key ASX stocks trade below their estimated fair value based on discounted cash flow assessments for June 2026. Notable undervalued stocks include Symal Group (45.5% discount), Magellan Financial Group (48.5%), and James Hardie Industries (10.4%) as market participants grapple with recent Wall Street tech sell-offs and Middle East geopolitical tensions. Magellan reported a 48.5% discount at A$8.91 versus a fair value of A$17.31, though dividend sustainability remains questioned. James Hardie trades at A$31.32 against an estimated A$34.95 value despite mixed earnings and high debt. Identifying such discrepancies offers avenues for investors amid uncertain broader market conditions.

Latest articles

Uranium Energy Drops 17% After Reporting Q3 Loss

Uranium Energy Drops 17% After Reporting Q3 Loss

9 June 2026
Uranium Energy shares plunged 17% to $10.43 after reporting a wider Q3 net loss of $52.3 million and no uranium inventory sales, overshadowing the start of production at Burke Hollow; heavy volume and a sharper drop than peers reflected investor concerns over execution risks and near-term earnings despite strong cash and no debt.
Elong Power Stock Rips 58%, Small Nasdaq Battery Play Goes Wild

Elong Power Stock Rips 58%, Small Nasdaq Battery Play Goes Wild

9 June 2026
Elong Power shares soared 58.3% to $1.22 in heavy Nasdaq trading, with volume topping 123 million, after a recent $6 million unit offering at $1.30 and a March 1-for-80 reverse split; despite the rally, the stock remained below the recent offering price, with filings showing a $5.57 million net loss for 2025, a $14 million working-capital deficit, and warnings of possible further dilution if more capital is needed.
Marathon Digital Shares Fall as Bitcoin Move Renews Focus on AI Strategy

Marathon Digital Shares Fall as Bitcoin Move Renews Focus on AI Strategy

9 June 2026
MARA shares plunged 4.3% to $13.19 as bitcoin slipped below $62,000, highlighting that despite efforts to pivot toward AI and data-center infrastructure, the stock remains tightly tied to bitcoin’s price, with recent earnings showing revenue and bitcoin holdings down sharply and ongoing risks if crypto weakness persists.
UiPath Falls Again as AI Stocks Face Selling

UiPath Falls Again as AI Stocks Face Selling

9 June 2026
UiPath shares slid 5% to $10.63 as investors dumped AI-linked tech stocks despite the company posting its first-ever GAAP profit and raising full-year guidance, with market pressure and doubts about rapid AI-driven growth weighing on the stock.
XRP price today: Ripple token bounces as DTCC listing and Iran war headlines steer crypto traders

XRP Price Holds $1.10 as Key Level for Traders

9 June 2026
XRP slid 2.6% to $1.14 as crypto markets lost momentum, leaving the token just above key $1.10 support defended after last week’s four-month lows; traders are watching $1.13-$1.14 as support and $1.15-$1.20 as resistance, with broader risk-off sentiment and weak ETF inflows pressuring prices, while a break below $1.10 could signal further downside.
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Previous Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Next Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Go toTop